基于单细胞CAF异质性的CT拓扑影像预测胰腺癌预后与辅助化疗获益
研究整合单细胞RNA测序与多队列转录组数据,识别出三种不良预后CAF亚群并构建九基因CAPR评分。基于CT拓扑数据分析开发ra-CAPR分类器,在122例机构队列和50例TCIA队列中验证。ra-CAPR在手术队列中独立预测总生存,辅助化疗在ra-CAPR低组绝对获益更大。
要点
- ra-CAPR基于CT拓扑特征,术前无创评估胰腺癌CAF不良亚群相关风险。
- ra-CAPR低组辅助化疗绝对获益大于高组(29.5个月 vs 17.0个月)。
- ra-CAPR跨队列特征分布偏移低于传统影像组学(26% vs 75%)。
核心结论
- 基于CT拓扑数据分析的ra-CAPR分类器可术前无创识别不良CAF亚群相关风险。
- ra-CAPR在手术队列中独立预测总生存(HR 1.42,P = 0.005)。
- 辅助化疗在ra-CAPR低组与高组均改善总生存,低组绝对获益更大(29.5个月 vs 17.0个月)。
研究设计与样本
- 研究共纳入1452例胰腺导管腺癌患者,涵盖转录组分析与影像分析。
- 整合24例单细胞RNA测序数据与TCGA-PAAD转录组数据,采用Scissor算法识别预后相关CAF亚群。
- 九基因CAPR评分在四个独立转录组队列中验证,共594例。
- CT拓扑数据分析分类器ra-CAPR在122例机构队列中开发,在50例TCIA队列中外部验证。
- 在657例独立手术队列中评估ra-CAPR的预后价值,并与传统影像组学对比。
关键影像表现/征象
- CT拓扑数据分析提取的拓扑特征可反映胰腺癌CAF不良亚群的肿瘤微环境空间结构。
诊断标准与关键数值
- ra-CAPR在跨队列验证中AUC为0.774,传统影像组学AUC为0.715。
- 另一跨队列比较中ra-CAPR AUC为0.744,传统影像组学AUC为0.621。
- ra-CAPR跨队列特征分布偏移为26%,传统影像组学为75%。
- 手术队列中ra-CAPR独立预测总生存,HR 1.42,P = 0.005。
临床应用与阅片要点
- ra-CAPR可在术前CT上无创评估胰腺癌患者的CAF相关风险分层。
- ra-CAPR低组患者辅助化疗绝对获益更大,可用于辅助治疗决策参考。
局限性
- ra-CAPR开发队列为单中心机构队列,样本量为122例。
- 外部验证队列TCIA样本量仅50例,规模较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Cancer-associated fibroblasts (CAFs) are central drivers of PDAC progression and therapeutic resistance, yet their preoperative clinical utility remains unexplored. We aimed to translate single-cell CAF heterogeneity into a CT-based framework for preoperative risk stratification and adjuvant chemotherapy stratification in PDAC.
MATERIALS AND METHODS: A total of 1452 PDAC patients were included across transcriptomic and imaging analyses. Single-cell RNA sequencing data from 24 patients were integrated with TCGA-PAAD bulk transcriptomics using the Scissor algorithm to identify prognosis-associated CAF subpopulations. A nine-gene CAPR score was validated across four independent transcriptomic cohorts (n = 594). A CT-based topological data analysis (TDA) classifier (ra-CAPR) was developed in an institutional cohort (n = 122), externally validated in the TCIA cohort (n = 50), and evaluated in an independent surgical cohort (n = 657), with performance benchmarked against conventional radiomics.
RESULTS: Three adverse CAF subpopulations (ECM-remodelling myCAF, hypoxic CAF, and iCAF_chemokine) were identified, defining an immune-excluded, mutationally-burdened, and chemoresistant phenotype across validation cohorts. The TDA-based ra-CAPR classifier demonstrated superior cross-cohort robustness over conventional radiomics (AUC 0.774 vs. 0.715; 0.744 vs. 0.621), accompanied by markedly lower cross-cohort feature distributional shift (26% vs. 75%). In the surgical cohort, ra-CAPR independently predicted overall survival (HR 1.42, P = 0.005). Adjuvant chemotherapy improved OS in both ra-CAPR subgroups, with a larger absolute gain in ra-CAPR-low patients (29.5 vs 17.0 months).
CONCLUSION: By translating adverse CAF subpopulation signatures into a CT-based topological biomarker, ra-CAPR enables individualized preoperative risk stratification and may facilitate risk-adapted postoperative management.
引用
- Wang, Xie, Tang, et al. Topological imaging of single-cell CAF heterogeneity for predicting prognosis and adjuvant chemotherapy benefit in pancreatic cancer. Eur J Radiol. 2026. PMID: 42435622. doi:10.1016/j.ejrad.2026.113075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。